The common objective of therapeutic attempts to inhibit cholesterogenesis, whether by nutritional or pharmacological means, is to limit the availability of cholesterol in order to treat hyperlipidaemia, a risk factor for the development of atherosclerosis and coronary heart disease. Consideration of this role of cholesterol must take account of modern theories of lipoprotein transport and function. In particular, the identification of HDL* as a negative risk factor for atherosclerosis, because of its function in centripetal transport, has stimulated recent research to concentrate on ways of specifically lowering the levels of LDL and VLDL.
Certain of the common types of hyperlipidaemia may be characterized by elevated cholesterogenesis but even basal rates of synthesis can contribute more than 50% of the daily input so that an inhibition, if consistently effective and safe. has clinical potential. Various classes of compound have been identified as inhibitors of individual steps of the sterol biosynthetic pathway (Fears, 1983 ) but action at a late stage leads to the accumulation of deleterious intermediates. The reactions catalysed by mevalonate kinase and prenyl transferase have been discussed as possible sites for pharmacological intervention (Gibons e/ al.. 1982) but most attention has been devoted to the control of HMG-CoA reductase (EC 1.1.1.34), the enzyme usually considered to be rate-limiting for the pathway.
Cornpactin and mevinolin: comparison of species
Studies on the regulation of the pathway have been advanced by the use of compactin (ML-236B. mevastatin). which was isolated from the culture broth of Penicillium brevicompactum and comprises a hexahydronaphthalene skeleton substituted with a D-hydroxy-8-lactone (Fears, 1981) . Compactin (0.1 ,UM) competitively inhibits HMG-CoA reductase activity in rat liver microsomes (0.70 5 0.03 nmol/30min incubation per mg of protein compared with the control rate of 4.8 f 0.59 nmol/ 30min per mg of protein: n = 5, P<O.Ol) but the rate is restored to the control level (4.0+0.35nmol/30min per mg of protein) when compactin is washed out of the microsomes. Equivalent inhibition by compactin in vitro is also observed for that relatively small proportion of HMG-CoA reductase believed to be active in viuo (measured in microsomes prepared using ~O~M -N~F ) and for the elevated enzyme activity induced in cholestyramine-treated rats and also in microsomes isolated from rat small intestine.
Daily oral dosing of compactin to rats also transiently inhibits cholesterogenesis in liver and small intestine in vivo (Fears et al.. Abbreviations: HDL. high-density lipoprotein: LDL. lowdensity lipoprotein: VLDL. very-low-density lipoprotein: H M G Co A. p h y d r n x y B~methylglutaryl~CoA. 1980) when rates are measured by using )H,O, a method considered to give the most meaningful results (Fears, 1978) but there is no decrease in the serum concentration of cholesterol (Table 1 ). In fact, there is little net change in the mass of cholesterol synthesized during the 24 h-period after dosing because an early inhibition of HMG-CoA reductase leads to subsequent induction of enzyme synthesis with expression of increased activity. A similar response is observed in cell cultures, possibly with concomitant induction of HMG-CoA synthase synthesis (Luskey et al., 1982) .
However, hypocholesterolaemic activity is observed in dogs (Table I ) in association with decreases in serum triacylglycerol and phospholipid levels. Studies in dogs on mevinolin, the 6a-methyl analogue of compactin (Kovanen et al., 1981) , have demonstrated that inhibition of HMG-CoA reductase activity can lead not only to impaired VLDL synthesis but also to an increase in the rate of LDL catabolism by inducing the hepatic apoprotein B/E receptor. presumably in order to satisfy sterol requirements in the liver by uptake from the circulation. It is not established whether induction of the receptor is confined to the liver but this response is not essential for some expression of LDLlowering activity because compactin is also hypocholesterolaemic in the WHL rabbit with a genetic receptor defect. It is not clear why compactin is hypolipidaemic in dogs but not rats. The receptor for apoprotein B can be induced in rats by other pharmacological agents that deplete sterol pools and the dose-response relationship in vitro for HMG-CoA reductase activity is similar (Fig. I) . It seems likely that the species-specificity for compactin can be explained by relative rates of drug metabolism, and hence expression of homeostatic response, rather than by qualitative differences in the control of lipid metabolism.
Compactin lowers the serum concentration of cholesterol in patients and mevinolin is active in volunteers ( Table 2) . The action appears to be specific for LDL in contrast with the response in dogs (Table I) , where HDL is also lowered, presumably because dog HDL, is rich in apoprotein E and so is recognized and bound by the induced hepatic receptor. The lack of a dose-response relationship in the published studies (Table  2) suggests that the optimum dose may be low; there were no serious side effects reported and in particular steroid hormone production requiring cholesterol precursor, was maintained.
Inhibition of HMG-CoA reductase in vitro
Studies in vitro have identified potentially deleterious consequences of markedly inhibiting mevalonate production, particularly in cells with a rapid rate of turnover. Thus, inhibition of cholesterogenesis in the small intestine can affcct the motional freedom of lipids in the microvillus membrane (Brasitus & Schachter. 1982). also decreasing crypt-cell renewal and villous-cell differentiation, perhaps consistent with impaired enterohepatic recirculation (Fears, 1983) .
Compactin at very high concentrations affects the function of other cells in culture, possibly by interrupting the supply of key non-sterol intermediates, e.g. squalene, dolichol, ubiquinone, isopentenyl adenine, rather than cholesterol itself (Fears, 198 I) . Thus compactin inhibits concanavalin A induction of DNA synthesis in mouse spleen lymphocytes (Perkins et al., 1982) and this inhibition is reversed by mevalonate but not by cholesterol or by isopentenyl adenine; the latter observation is in contrast with the restoration of DNA synthesis in synchronized cultures of BHK-21 cells (Quesney-Huneeus et al., 1980) . The existence of a key, unidentified, mevalonate metabolite is supported by studies with human peripheral blood lymphocytes (Larson ef al., 1982) and Swiss 3T3 cells (Schmidt et al., 1982) .
In general, this non-sterol product of mevalonate seems to be critical for cell proliferation in growing cells but for maintenance of shape in confluent, non-growing cells (Cohen el al.,  1982) .
Other isoprenoids have well-defined functions. As discussed previously (Fears, 198 1) the biosynthesis of dolichol is important to maintain protein N-glycosylation. Moreover it has been suggested recently (Kean, 1982) that dolichyl phosphatemannose may participate not only as a substrate for amannosylation but also as a regulator of biosynthesis of oligosaccharide-lipids. However, the possible co-ordinate control of dolichol and cholesterol synthesis is less likely if it is established that the respective pathways occur in different cellular compartments (Hemming, 19 82) .
Recent chemical developments
Inhibitors related to compactin and mevinolin are obtained from other micro-organisms and simpler, less active, mevalonolactone derivatives have also been synthesized (Fears, 1983) . Approaches to the total synthesis of (+)-compactin have recently been published, the first by Wang and co-workers (Wang et af., 1981) and if these routes can be adapted for the production of analogues then valuable information may be obtained on the attributes required for optimal activity. It is noteworthy that in addition to binding at the active site, compactin and mevinolin may bind to other regions of HMG-CoA reductase, inducing a change in protein conformation that is essentially irreversible (Rogers & Rudney, 1982) .
Other applications for compactin and related compounds
In addition to the potential therapeutic use of inhibitors of HMG-CoA reductase as hypolipidaemic agents and to their employment as tools to study the detailed control of mevalonate flux, the wide phylogenic occurrence of HMG-CoA reductase suggests a possible use in the control of metabolism of certain plants and insects. For example, compactin inhibited HMGCoA reductase in the corpora allata of the tobacco hornworm Manduca sexta (Monger et al., 1982) , the K, (0.9nM) being similar to that measured in mammalial cells. Furthermore, injection of compactin into larvae induced darkening of the cuticle, indicative of a deficiency of the isoprenoid juvenile hormone. The aphid, Schizaphis graminium, uses mevalonate by the trans-methylglutaconate shunt pathway for the synthesis of long-chain fatty alcohols in cuticular wax (Nes et al., 1982) , which suggests another type of control based on inhibition of HMG-CoA reductase.
In conclusion, using compactin and its analogues we are now able to evaluate in detail the beneficial as well as the possible toxicological consequences of manipulating HMG-CoA reductase. Whether this approach has clinical use is still too early to say but for the biochemist these pharmacological tools may enable significant advances to be made both as regards our understanding of the control of this enzyme and also with respect to the comparison of possible interspecies differences in lipid metabolism. 
